Moderna Reports Q3 2026 Profit Growth Driven by International Vaccine Sales
Moderna (MRNA) reported a significant financial turnaround in the third quarter of 2026, posting a net income of $162 million compared to a loss of $200 million in the previous year. Revenue grew 29% year-over-year to $1.3 billion, fueled primarily by increased COVID-19 vaccine sales in international markets and strong U.S. respiratory vaccine volumes. The company demonstrated improved financial discipline, reducing R&D expenses by 27% through organizational efficiencies. Despite a $950 million litigation settlement, Moderna's cash position strengthened to $8 billion following the issuance of zero-percent convertible notes. Looking ahead, management raised full-year revenue guidance to a 15%-25% growth range. Clinical developments provided mixed signals: while the melanoma Phase 3 study showed a 42% reduction in recurrence or death risk using intismeran, the Norovirus program was halted after failing to meet interim success criteria. Additionally, the FDA granted approval for mFLUSIVA across various adult age groups.
Tickers: $MRNA
Topics: COVID-19 vaccine sales EPS guidance net income revenue growth